Table 1.
Demographic and clinical parameters of 50 patients with mRCC treated with sunitinib
| Variables | All cases (n = 50) | CR/PR (n = 12) | SD (n = 22) | PD (n = 6) | NE (n = 10) | P value |
|---|---|---|---|---|---|---|
| Age [median (IQR)] | 64 (58–71) | 63 (56–77) | 63 (57–67) | 61 (56–66) | 70 (64–76) | 0.16† |
| Follow-up months [median (IQR)] | 20 (10–25) | 21 (15–25) | 22 (13–30) | 12 (6–23) | 18 (7–25) | 0.38† |
| Gender | 0.51‡ | |||||
| Male | 40 (80 %) | 10 (83 %) | 17 (77 %) | 6 (100 %) | 7 (70 %) | |
| Female | 10 (20 %) | 2 (17 %) | 5 (23 %) | 0 (0 %) | 3 (30 %) | |
| Prior nephrectomy | 0.95‡ | |||||
| Yes | 44 (88 %) | 11 (92 %) | 19 (86 %) | 5 (83 %) | 9 (90 %) | |
| No | 6 (12 %) | 1 (8 %) | 3 (14 %) | 1 (17 %) | 1 (10 %) | |
| Tumor histology | 0.41‡ | |||||
| Clear cell | 40 (80 %) | 11 (92 %) | 15 (68 %) | 5 (83 %) | 9 (90 %) | |
| Non-clear cell | 4 (8 %) | 0 (0 %) | 4 (18 %) | 0 (0 %) | 0 (0 %) | |
| Unknown | 6 (12 %) | 2 (17 %) | 3 (14 %) | 1 (17 %) | 1 (10 %) | |
| Concomitant sarcomatoid variant | 2 (4 %) | 0 (0 %) | 0 (0 %) | 1 (17 %) | 1 (10 %) | |
| ECOG-PS | 0.06‡ | |||||
| 0/1 | 41 (82 %) | 11 (92 %) | 19 (86 %) | 5 (83 %) | 5 (50 %) | |
| 2/3 | 9 (18 %) | 1 (8 %) | 3 (14 %) | 1 (17 %) | 5 (50 %) | |
| Metastatic sites | 0.24‡ | |||||
| Lung | 28 (56 %) | 7 (58 %) | 12 (55 %) | 5 (83 %) | 4 (40 %) | |
| Lymph nodes | 12 (24 %) | 3 (25 %) | 8 (36 %) | 2 (33 %) | 1 (10 %) | |
| Bone | 19 (38 %) | 2 (17 %) | 10 (45 %) | 0 (0 %) | 5 (50 %) | |
| Liver | 4 (8 %) | 1 (8 %) | 1 (5 %) | 1 (17 %) | 1 (10 %) | |
| Pancreas | 2 (4 %) | 2 (17 %) | 0 (0 %) | 0 (0 %) | 0 (0 %) | |
| Heng risk group | 0.016‡ | |||||
| Favorable | 10 (20 %) | 3 (25 %) | 5 (23 %) | 1 (17 %) | 1 (10 %) | |
| Intermediate | 29 (58 %) | 8 (67 %) | 14 (63 %) | 3 (50 %) | 4 (40 %) | |
| Poor | 11 (22 %) | 1 (8 %) | 3 (14 %) | 2 (33 %) | 5 (50 %) | |
| Serum CRP (mg/dL) (mean ± SEM) | 2.70 ± 0.61 | 1.35 ± 0.78 | 2.79 ± 0.90 | 2.62 ± 1.43 | 4.18 ± 1.98 | 0.41† |
| Serum sodium (mmol/L) (mean ± SEM) | 139.4 ± 0.38 | 139.8 ± 0.59 | 140.3 ± 0.43 | 138.7 ± 1.26 | 137.4 ± 1.08 | 0.09† |
IQR interquartile range; ECOG-PS Eastern Cooperative Oncology Group-perfomance status; CRP C-reactive protein; CR complete response; PR pertial response; SD stable disease; PD progressive disease; NE not evaluated; SEM standard error of mean
†Kruskal–Wallis test; ‡ Chi square test or Fisher’s exact test